Business Wire

NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate

Jaa

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).

“The real-world results from these studies of diverse patient populations on three continents reaffirm the sustained benefits of the UroLift System as an accepted standard of care treatment for patients with BPH,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “We are pleased that we continue to see results from real-world studies in line with our randomized pivotal study, demonstrating that the UroLift System is a safe and effective minimally invasive treatment that offers men long-term relief from the symptoms of BPH.”

Five Studies Show Significant Relief and Improved Quality of Life with UroLift System
The “Real-World Experience” study, which enrolled 156 patients at the Norfolk & Norwich University Hospital in the U.K., compares outcomes of patients with BPH who received treatment with the UroLift System in a real-world setting to those seen in clinical studies.

The data, presented by Mark Rochester, M.D., consultant urological surgeon of Norfolk and Norwich University Hospitals NHS Foundation Trust U.K., demonstrates International Prostate Symptom Score (IPSS) improvement for patients treated with the UroLift System in a real-world setting, as well as improved quality of life (QoL) and peak flow rate (Qmax) at both the three and six-month follow up timepoints. At three months, patients experienced an average improvement of 10.0 points in IPSS, 2.2 points in QoL and 4.8 mL/s in Qmax. These results were statistically not different from those observed in the pivotal L.I.F.T. study.

“The excellent results of this large study were consistent with the pivotal L.I.F.T study,” said Dr. Rochester. “These outcomes demonstrate that the UroLift System can be used to treat patients with BPH in the real world safely and effectively.”

The “Does Size Matter?” study, which evaluates the UroLift System as a treatment for BPH in men with small and large prostate volumes, was presented by Gregory McMahon, D.O., urological surgery resident of Rowan University of Osteopathic Medicine (Stratford, N.J.), and Thomas Mueller, M.D., urologist of New Jersey Urology (Voorhees, N.J.). Both patient cohorts from this single-center study were treated in an office setting for a six-month period. Data from this study shows that men with small and large prostates experienced statistically significant improvement in symptoms and quality of life when treated for BPH with the UroLift System. At six months, mean IPSS decreased by 17.6 and 13.2, and QOL improved by 2.5 and 2.6 in the small and large prostate groups, respectively.

“Results from this study demonstrate the versatility of the UroLift System as an effective treatment for a wide range of patients and that it can be safely performed in an office setting. It is especially gratifying to see that results at an experienced center such as ours can meet or exceed those observed in the L.I.F.T. study,” said Dr. Mueller.

Three additional real-world studies were presented at the conference, each showing favorable results and improved outcomes for patients with BPH who received treatment with the UroLift System:

  • The Management of Acute Urinary Retention Study, presented by Ashok J. Kar, M.D., director of robotic and minimally invasive surgery St. Joseph Hospital of Orange (Orange, Calif.), reviewed the outcomes of patients who were treated with the UroLift System for acute urinary retention due to BPH. All patients from this study had indwelling foley catheters in place and were treated exclusively in an office setting for an 18-month period. The results demonstrated that 90% of the patients became catheter-free within three months after treatment.
  • Data presented by Campbell F. Bryson, M.D., chief urology resident of Yale New Haven Hospital (Princeton, N.J.), from a single-center, first-time, real-world study closely resembles results from the pivotal L.I.F.T trial, showing robust improvements in symptoms and quality of life for patients treated for BPH with the UroLift System.
  • Results from an Early Experience study presented by Justin Chee, M.D., consultant urological surgeon of Western Health (Melbourne, Australia), show that patients treated for symptomatic BPH with the UroLift System in a public hospital setting experienced improvement in symptoms and quality of life with preserved sexual function.

About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Nearly 70,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.

About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

Mark Rochester and Thomas Mueller are paid consultants to NeoTract | Teleflex Interventional Urology.

###

MAC00843-02 Rev A

Contact information

For Teleflex Incorporated
Jake Elguicze
610.948.2836
Treasurer and Vice President, Investor Relations
or
Media
Nicole Osmer, 650.454.0504
nicole@healthandcommerce.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

PMC Group International Announces Acquisition of Product Line from Solvay, SA16.1.2019 03:33Tiedote

PMC Ouvrie SAS, France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of a hydrocolloid product line from the Belgium based Solvay, SA. These products will be sold globally to the home and personal care (HPC), industrial and coatings markets under the trade names Rhodicare CFT, Rhodicare D, Rhodicare H, Rhodicare S, Rhodicare T, Rhodicare XC, Rhodopol 23, Rhodopol G, Rhodopol T, Rhodopol TG, Rhodopol Extra 2, and Rhodopol Extra 2 Clear. “The acquisition of these products made by fermentation processes emphasizes our increasing interest in products made by green chemistry and biological processes,” said Dr. Raj Chakrabarti, Head of PMC Group International. “The acquired hydrocolloids fit synergistically with the functional product lines of PMC Ouvrie, which has long been a leading supplier of defoamers to bio-based process technologies,” he added. ABOUT PMC PMC Group is a US based growth oriented, dive

TurbineAero, Inc. Announces Acquisition of APU Piece Part Repair Business from the Triumph Group16.1.2019 02:51Tiedote

TurbineAero, a portfolio company of The Gores Group, announced today the acquisition of the APU piece part repair product line (“RPL”) from Triumph Aviation Services Asia, Ltd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005959/en/ TurbineAero Repair–Asia, APU Operations Team (Photo: Business Wire) The acquisition of this business segment integrates APU piece part repair into the APU Systems MRO in TurbineAero’s Asia facility which increases in-house capabilities, improves turn-times and assures extra cost reduction. Effective immediately, the integration will take place in TurbineAero Asia’s new Thailand based 80,000 square foot facility which will house up to 250 employees and will handle high technological testing, maintenance, repair and overhaul activities for aircraft components and systems for our worldwide customers, including APU MRO, LRUs and APU part repair. “We are delighted to add the APU piece part rep

INDYCAR Names NTT as Entitlement Sponsor of IndyCar Series15.1.2019 20:20Tiedote

INDYCAR announced today during the North American International Auto Show that global information technology and communications leader NTT has signed a multi-year agreement to become the IndyCar Series Title Partner. In addition, NTT becomes the Official Technology Partner of INDYCAR, the IndyCar® Series, Indianapolis Motor Speedway, the Indianapolis 500 and NASCAR’s the Brickyard 400 beginning in 2019. INDYCAR will partner with NTT to deliver digital innovations that enhance the fan experience. These innovations include the evolution of INDYCAR’s mobile application and adoption of NTT’s proprietary Smart Platform to support the sport and its venues in delivering better insights into the racing series. “NTT is proud to be associated with INDYCAR and accelerate the future of smart racing. Technological innovations have the potential to change the sport and fan experience drastically,” said Jun Sawada, President and CEO of NTT. “NTT, along with our partners, aims to bring the Smart World

MobileIron Recognized as a Partner in Google Led Android Enterprise Recommended Program for Enterprise Mobility Management Providers15.1.2019 20:20Tiedote

MobileIron (NASDAQ:MOBL), the secure foundation for modern work, today announced that it has been recognized by Google™ as a partner in its Android Enterprise Recommended program for Enterprise Mobility Management (EMM) providers. Android™ Enterprise Recommended validates those EMM solutions that meet an elevated set of requirements defined by Google, delivering advanced Android Enterprise features that are supported by highly knowledgeable teams specializing in modern Android security and management. “Enterprise transformation will be central to the second decade of Android computing. Offerings like Android Enterprise Recommended, OEM Config, and Google Play Protect create the perfect storm to support the millions of Android devices that are increasingly making their way to the enterprise,” said Simon Biddiscombe, CEO, MobileIron. “MobileIron is pleased to be a partner in the Android Enterprise Recommended program for EMMs. We are confident that our expertise in endpoint and device se

CSC Extends Fund Administration Reach into Asia Pacific15.1.2019 18:00Tiedote

CSC has extended their private equity and real estate fund administration services into Asia. Third-party oversight of private equity and real estate funds is increasing due to the growing demand from investors for greater transparency and help navigating the regulatory requirements in this dynamic landscape. “A number of factors are creating opportunities in the private equity market in Asia, including strong deal growth, increasing reporting demands from investors, and pressure to commit unspent capital,” says Bill Popeo, president of CSC’s Global Financial Markets business. Liam McHugh, Fund Administration managing director, is leading the efforts in Asia, with office locations in Singapore, Hong Kong, and Shanghai. Prior to joining CSC, McHugh served in various executive capacities at Apex Fund Services and Equinoxe Alternative Investment Services in the APAC region and Ireland. “CSC’s private ownership status ensures the stability that is required of a service provider in a fragme

UAEREP’s First Cycle Awardees Present Outstanding Final Project Results At the 3rd IREF15.1.2019 17:29Tiedote

The UAE Research Program for Rain Enhancement Science’s 3rd International Rain Enhancement Forum (IREF) today featured the final project results of its 1st Cycle awardees at the 2019 Abu Dhabi Sustainability Week (ADSW). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005523/en/ 3rd International Rain Enhancement Forum Reveals Results of the Researches of its First Cycle (Photo: AETOSWire) In the presence of a distinguished audience of VIP dignitaries, diplomats, stakeholders and scientists, Dr Linda Zou, Professor Volker Wulfmeyer, Professor Masataka Murakami, presented the final results of innovative research advancing rain enhancement science in the UAE and beyond. The three awardees that presented the successful outcomes of original research projects completed within a 3-year time scale are: Professor Linda Zou, a Professor at the Khalifa Institute of Science and Technology, has fabricated, tested and validated nove

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme